Who Owns Enovis Company?

Enovis Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Enovis today?

Enovis spun out of Colfax on April 4, 2022, becoming a focused ortho medtech public company (NYSE: ENOV). The change shifted control from a diversified parent to a broadly held public shareholder base led by institutions and active investors. Founder-era influence waned as institutional ownership grew.

Enovis is majority-owned by institutional investors with a one-share-one-vote structure; founder family stakes are smaller and passive, while active funds and mutuals drive capital allocation and M&A moves. See Enovis Porter's Five Forces Analysis for strategic context.

Founders and Early Ownership of Enovis trace to Colfax Corporation, established in 1995 by Mitchell P. Rales and Steven M. Rales; the Rales family held controlling equity through RC/DC holding vehicles and early management co-investment, with control affirmed in SEC filings around the 2008 IPO.

Founders

Mitchell P. Rales and Steven M. Rales founded Colfax in 1995 and seeded initial capital from family investment vehicles.

Initial Ownership

The Rales family held supermajority pre-IPO stakes via affiliates, with precise percentages not publicly itemized in early filings.

Capital Sources

Early capital came from founders and related entities rather than traditional venture capital or outside private equity.

Management Equity

Management co-invested and received options/RSUs, typically with a four-year vesting schedule and a one-year cliff post-IPO.

Governance Protections

Shareholder and registration rights agreements around the 2008 IPO included buy-sell and change-of-control protections to preserve founder influence.

Dilution Over Time

Acquisitions such as ESAB and DJO (2019) diluted founder percentage ownership, but board representation maintained Rales influence.

SEC filings and the 2008 IPO disclosures show the Rales family as controlling shareholders; staged liquidity via the IPO and follow-on offerings broadened the public float and reduced concentrated control while leaving notable insider ownership during early years.

Key facts and implications

Early ownership shaped governance and later public ownership dynamics; relevant for those researching Enovis ownership and shareholder structure.

• The Rales family held a supermajority pre-2008 IPO via RC/DC-style holding entities.
• Early financing was founder-led; no major VC rounds were recorded in initial stages.
• Management equity followed standard vesting: 4-year vest with a 1-year cliff common post-IPO.
• Dilution occurred as Colfax/Enovis grew through acquisitions, but founder board influence persisted.

For further context on business operations and revenue drivers related to ownership impacts, see Revenue Streams & Business Model of Enovis; for up-to-date institutional and insider stakes consult 2024–2025 SEC beneficial ownership filings and 13F reports to identify Enovis institutional investors and Enovis largest shareholders.

Enovis SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key transactions reshaped Enovis ownership: the 2008 Colfax IPO established a public float with the Rales family as largest holders; the 2019 DJO Global acquisition pivoted the group to medtech and broadened institutional interest; the 2022 ESAB spin‑off and Enovis rebrand concentrated medtech assets and drove high institutional ownership.

The ownership evolution shifted Enovis from founder‑influenced governance toward an institutionally dominated shareholder base focused on M&A‑driven growth and operational leverage to support mid‑teens adjusted EPS targets.

Major stakeholders and ownership mix

As of 2024–2025 filings and Form 13F trends, ownership is concentrated among index/passive managers and active healthcare investors.

• Index/passive: Vanguard Group typically holding in the 10–13% range; BlackRock 7–10%; State Street 3–5%
• Active institutions: Wellington, T. Rowe Price, Wasatch, Invesco, Fidelity and specialist healthcare funds each often hold 1–5%
• Insiders: CEO, CFO and senior executives collectively low‑single‑digit percent via RSUs/options; individual insider stakes generally 1% or less
• Founding family: Rales family direct holdings in Enovis post‑spin are modest versus Colfax era, with diversified positions across holdings

Key data sources: Enovis DEF 14A, recent Form 13F snapshots (2024–2025), transaction announcements (DJO $3.15B; LimaCorporate 2024), and peer mid‑cap medtech benchmarks for institutional ownership.

For background on corporate changes and timelines see Brief History of Enovis

Enovis PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Enovis board of directors is composed of independent directors with medtech, orthopedics, finance and M&A backgrounds alongside management representation such as the CEO; the company uses a one-share-one-vote structure with no dual-class or founder shares. Institutional investors and proxy advisors play an outsized role in voting outcomes.

Enovis ownership is driven by institutional shareholders; the company’s governance record from 2023–2025 shows no dual-class shares, no golden shares, and no high-profile proxy fights, with routine votes on say-on-pay, equity plans and board refreshment.

Voting dynamics and influence

Proxy outcomes largely reflect the institutional investor base and guidance from proxy advisory firms, shaping director elections and compensation votes.

• Enovis uses one-share-one-vote — no dual-class or founder shares
• Proxy advisors (ISS/Glass Lewis) and top managers often control 30–40%+ of votes cast
• Directors are independent professionals; some have reputational links to large institutions but hold no formal representative seats
• Key governance items (2023–2025): say-on-pay, equity plan approvals, board refreshment — no major proxy contests

For context on company purpose and leadership priorities see Mission, Vision & Core Values of Enovis; for specifics on who owns Enovis company stock, Enovis top 10 shareholders 2025 and Enovis institutional investors consult the company’s 2025 proxy statement and recent 13F/beneficial ownership filings for up-to-date Enovis shareholders and insider ownership percentages.

Enovis Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Enovis ownership shifted meaningfully from 2023–2025 as institutional and passive holders increased exposure while management prioritized M&A over buybacks, raising net leverage temporarily and boosting European and Recon presence after the 2024 LimaCorporate deal.

Institutional rotations into healthcare and index rebalances increased holdings among Enovis institutional investors, while specialist healthcare funds raised weights as Recon and Sports Med outgrew legacy bracing segments.

2024 LimaCorporate acquisition

The acquisition closed in 2024, expanding Europe exposure and Recon mix, driving a pro forma revenue run-rate near $2.2–$2.3B.

Capital structure and funding

M&A funded via cash, debt, and equity capacity; net leverage rose to low- to mid-3x then began deleveraging as EBITDA expanded.

Shareholder mix trends

Passive ownership share continued to rise; healthcare specialists increased exposure and insider ownership stayed in the low-single-digit range.

Capital allocation and outlook

Management signaled focus on building a top-5 Recon platform via continued tuck-ins and innovation; no public activist contest or privatization signals through 2025.

For context on market positioning and target customers, see Target Market of Enovis.

Enovis Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔